Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival.
Galleu A, Milojkovic D, Deplano S, Szydlo R, Loaiza S, Wynn R, Marks DI, Richardson D, Orchard K, Kanfer E, Tholouli E, Saif M, Sivaprakasam P, Lawson S, Bloor A, Pagliuca A, Potter V, Mehra V, Snowden JA, Vora A, Kishore B, Hunter H, Apperley JF, Dazzi F. Galleu A, et al. Among authors: dazzi f. Br J Haematol. 2019 Apr;185(1):89-92. doi: 10.1111/bjh.15749. Epub 2019 Jan 13. Br J Haematol. 2019. PMID: 30637732 Free PMC article.
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.
Kaeda J, O'Shea D, Szydlo RM, Olavarria E, Dazzi F, Marin D, Saunders S, Khorashad JS, Cross NC, Goldman JM, Apperley JF. Kaeda J, et al. Among authors: dazzi f. Blood. 2006 May 15;107(10):4171-6. doi: 10.1182/blood-2005-08-3320. Epub 2006 Jan 31. Blood. 2006. PMID: 16449534 Free PMC article.
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, Foroni L, Rezvani K, Bua M, Dazzi F, Pavlu J, Klammer M, Kaeda JS, Goldman JM, Apperley JF. Marin D, et al. Among authors: dazzi f. Blood. 2008 Dec 1;112(12):4437-44. doi: 10.1182/blood-2008-06-162388. Epub 2008 Aug 20. Blood. 2008. PMID: 18716134 Free PMC article.
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.
Ibrahim AR, Paliompeis C, Bua M, Milojkovic D, Szydlo R, Khorashad JS, Foroni L, Reid A, de Lavallade H, Rezvani K, Dazzi F, Apperley JF, Goldman JM, Marin D. Ibrahim AR, et al. Among authors: dazzi f. Blood. 2010 Dec 16;116(25):5497-500. doi: 10.1182/blood-2010-06-291922. Epub 2010 Sep 10. Blood. 2010. PMID: 20833982 Free PMC article. Clinical Trial.
229 results